Adding drug to standard chemo shows promise for women with triple-negative breast cancer
12/19/2013
In a nationwide study of women with "triple-negative" breast cancer, adding the chemotherapy drug carboplatin or the angiogenesis inhibitor Avastin to standard chemotherapy drugs brought a sharp increase in the number of patients whose tumors shrank away completely, investigators reported at the 2013 San Antonio Breast Cancer Symposium.
Promising breast cancer drugs put on fast track
12/19/2013
The first investigator results from an unprecedented nationwide effort to test promising new breast cancer drugs before the tumor is removed were presented during the 2013 San Antonio Breast Cancer Symposium.
Cancer death risk increases with chronic kidney disease
12/18/2013
Cancer sufferers are more likely to die from their condition if their kidneys are not functioning properly, a new study published online in the American Journal of Kidney Diseases claims.Dr. Germaine Wong from the University of Sydney led the research, which shows that even mild to moderate reduction in kidney function increased the rate of cancer mortality.
Major imaging study uses Siemens MR technology to transform disease research
12/18/2013
UK Biobank, a world-leading health research resource, is putting preparations in place for a study to help scientists gain a more detailed understanding of a wide range of diseases including dementia, cancer and heart, bone and brain disorders.
Curie-Cancer and Strand launch Curie Image Database
12/18/2013
Curie-Cancer, the body responsible for developing Institut Curie's industry partnership activity, and Strand Scientific Intelligence, Inc. (Strand) announce the launch of the Curie Image Database (CID), a breakthrough image analysis and management platform that they developed jointly over the last two years at the Cell and Tissue Imaging Core Facility of the Institut Curie (PICT-IBiSA).
Research backs risk-reduction surgery for ovarian cancer
12/18/2013
A study by Manchester scientists backs preventative surgery to improve survival for women who are at greater risk of getting ovarian cancer and suggests it appears helpful for women at risk of getting breast cancer because of genetic faults. Women who carry, a fault in one of two high-risk genes known as BRCA1 or BRCA2, have an increased risk of dying from breast and/or ovarian cancer.
Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces that the US Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to initiate a Phase 3 pivotal study of ST10, its novel oral iron-replacement therapy, for the treatment of iron deficiency anaemia...
Research backs risk-reduction surgery for ovarian cancer
12/18/2013
A study by Manchester scientists backs preventative surgery to improve survival for women who are at greater risk of getting ovarian cancer and suggests it appears helpful for women at risk of getting breast cancer because of genetic faults. Women who carry, a fault in one of two high-risk genes known as BRCA1 or BRCA2, have an increased risk of dying from breast and/or ovarian cancer.
A stop sign for cancer
12/18/2013
A particularly aggressive form of leukemia is the acute lymphoblastic leukemia (ALL). It is especially common among children and very difficult to treat. Researchers from the University of Veterinary Medicine, Vienna have now discovered completely new targets for the treatment of blood cancers.
Decoding the link between calcium deficiency and colon cancer
12/18/2013
A tiny, transparent fish embryo and a string of surprises led scientists to a deeper understanding of the perplexing link between low calcium and colon cancer.By studying zebrafish embryo skin, University of Michigan researchers decoded cell messages underlying abnormal colonic cell growth of the kind that can lead to tumors and colon cancer in calcium deficient individuals.